The pooled results from 9 studies (OS) and 7 studies (PFS) demonstrated significant differences in survival outcomes between lung cancer patients with COPD and those without COPD following PD-1/PD-L1 inhibitor therapy. This evidence concerns the gene CD274 and lung cancer.